发明公开
EP3253384A2 MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS
审中-公开
用于治疗和预防肿瘤的MEBENDAZOLE多晶体
- 专利标题: MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS
- 专利标题(中): 用于治疗和预防肿瘤的MEBENDAZOLE多晶体
-
申请号: EP16747414.7申请日: 2016-02-08
-
公开(公告)号: EP3253384A2公开(公告)日: 2017-12-13
- 发明人: BAI, Ren-yuan , STAEDTKE, Verena , JOSHI, Avadhut D. , RIGGINS, Gregory J.
- 申请人: The Johns Hopkins University
- 申请人地址: 3400 North Charles Street Baltimore, MD 21218 US
- 专利权人: The Johns Hopkins University
- 当前专利权人: The Johns Hopkins University
- 当前专利权人地址: 3400 North Charles Street Baltimore, MD 21218 US
- 代理机构: Murgitroyd & Company
- 优先权: US201562112706P 20150206
- 国际公布: WO2016127168 20160811
- 主分类号: A61K31/4184
- IPC分类号: A61K31/4184 ; A61K9/16 ; A61K9/28 ; A61P35/00
摘要:
Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent.
公开/授权文献
- EP3253384B1 MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS 公开/授权日:2021-12-15
信息查询
IPC分类: